Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis

Zanchetta, José R.; Hakim, Carina; Lombas, Carola

doi:10.1016/j.curtheres.2005.01.003

Cited by 11 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The persistence rates reported with teriparatide in these studies compare favorably with 1-year rates reported for other osteoporosis therapies, including oral bisphosphonates (24-93%), raloxifene (18-86%), and hormone replacement therapy (23.5-90%) 4,6,7,24,[33][34][35][36][37][38][39][40][41][42] .…”

Section: Discussionsupporting

confidence: 67%

Use of an educational support program to assist patients receiving injectable osteoporosis treatment: experience with teriparatide

Nogués

Rentero

Rodríguez³

2013

Current Medical Research and Opinion

View full text Add to dashboard Cite

These results show that patients from all provinces in Spain with severe osteoporosis receiving teriparatide and enrolled in an educational support program had high persistence and satisfaction with the program. However, no control group was included in these analyses and it is possible that selection bias occurred. It is suggested that patient-based strategies similar to this could be beneficial for all long-term treatments.

show abstract

Section: Discussionsupporting

confidence: 67%

Use of an educational support program to assist patients receiving injectable osteoporosis treatment: experience with teriparatide

Nogués

Rentero

Rodríguez³

2013

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…Systemic conditions affect bone structure [1]. It has been shown that more than 50% of people affected by chronic diseases arbitrarily discontinue therapy within one year [2], intensifying the impact of this known relationship. Takaishi et al [3] suggested that the possible association between alveolar bone mineral density (measured in intraoral radiographs) and poor general mineral condition was a predictor of vertebral fracture risk.…”

Section: Introductionmentioning

confidence: 99%

Influence of General Mineral Condition on Collagen-Guided Alveolar Crest Augmentation

2020

View full text Add to dashboard Cite

The local regeneration of bone defects is regulated by general hormone, enzyme, ion, and vitamin levels. General diseases and dysregulation of the human mineral system can impact this process, even in alveolar crest. The aim of this study is to investigate a relation between bone density, measured in two-dimensional X-rays, and general mineral condition of patients. The study included 42 patients on whom tooth extractions were performed. Data were divided into two groups: the region where collagen scaffold (BRM) was used and the reference region of intact normal bone (REF). Two-dimensional intraoral radiographs were taken in all cases just after the surgery (00 M) and 12 months later (12 M). Thyrotropin (TSH), parathormone (PTH), Ca2+ in serum, HbA1c, vitamin 25(OH)D3, and spine densitometry were checked. Digital texture analysis in MaZda 4.6 software was done. Texture Index (TI: BRM 1.66 ± 0.34 in 00 M, 1.51 ± 0.41 in 12 M, and REF 1.72 ± 0.28) and Bone Index (BI: BRM 0.73 ± 0.17 in 00 M, 0.65 ± 0.22 41 in 12 M, and REF 0.80 ± 0.14) were calculated to evaluate bone regeneration process after 12 months of healing (TI (p < 0.05) and BI (p < 0.01) are lower in BRM 12 M than in REF). This showed a relation between BI and TSH (R2 = 26%, p < 0.05), as well as a between BI and patient age (R2 = 65%, p < 0.001), and a weak relation between TI and TSH level (R2 = 10%, p < 0.05). This study proved that a collagen scaffold can be successfully used in alveolar crest regeneration, especially in patients with a high normal level of TSH in the middle-aged population.

show abstract

Non-compliance: the Achilles' heel of anti-fracture efficacy

et al. 2007

View full text Add to dashboard Cite

About 50% of patients fail to comply or persist with anti-osteoporosis treatment regimens within 1 year. Poor compliance is associated with higher fracture rates. Causes of poor compliance are unknown. As it is not possible to predict poor compliance, close monitoring of compliance is needed. Despite evidence supporting the anti-fracture efficacy of several pharmacological agents, approximately 50% of patients do not follow their prescribed treatment regimen and/or discontinue treatment within 1 year. Poor compliance is associated with higher fracture rates and increased morbidity, mortality and cost. However, as poor compliance, even to placebo, is associated with adverse outcomes, the higher morbidity appears to be only partly the result of lack of treatment: as yet, undefined characteristics place poor compliers at higher risk of morbidity and mortality. Only a small proportion (e.g., 6%) of the variability in compliance is explained by putative causal factors such as older age, co-morbidity or greater number of medications. Regimens with longer dosing intervals, such as weekly dosing, improve compliance, persistence and outcomes, but only modestly. As it is not possible to predict poor compliance, close monitoring of compliance should be an obligatory duty in clinical care. How this is best achieved has yet to be established, but poor persistence occurs as early as 3 months of starting treatment, indicating the need for early monitoring.

show abstract

Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis

Cited by 11 publications

References 15 publications

Use of an educational support program to assist patients receiving injectable osteoporosis treatment: experience with teriparatide

Use of an educational support program to assist patients receiving injectable osteoporosis treatment: experience with teriparatide

Influence of General Mineral Condition on Collagen-Guided Alveolar Crest Augmentation

Non-compliance: the Achilles' heel of anti-fracture efficacy

Contact Info

Product

Resources

About